Latest findings from the second phase of testing indicate that amlitelimab may be a top-performing contender for sustained treatment effectiveness in managing eczema.

RemeGen Showcases Study of Unique Disitamab Vedotin (RC48) in Treating Cervical Cancer through Verbal Presentation at 2024 ESGO Event.

Sensorion Reveals Achievement of Main Goal in Phase 2a Trial of SENS-401 for Preserving Remaining Hearing Function.

Celltrion USA has finalized their application for a biologic license to the U.S. Food and Drug Administration for CT-P39, their alternative biosimilar to XOLAIR (omalizumab).

Wegovy® receives green light in the USA to diminish heart-related health hazards for those excessively heavy or with obesity coupled with confirmed heart conditions.

BeiGene, Ltd., a global oncology-focused biopharma, announced FDA's fast-track approval for its cancer drug BRUKINSA(zanubrutinib).

Eli Lilly and Company announced that the FDA will convene its Advisory Committee to discuss Phase 3 results of the TRAILBLAZER-ALZ 2 study on the efficacy and safety of donanemab in early Alzheimer's.

Regor Therapeutics Group has announced the launch of its Phase 2 trial on RGT-075, an oral, highly selective GLP-1 receptor agonist.

Amylyx Pharmaceuticals released initial results from their Phase 3 PHOENIX study, a 48-week global, randomized, double-blind, placebo-controlled trial, assessing AMX0035 in ALS patients.

VISEN Reveals China's Endorsement of Submission for the Biologic Drug License Concerning Lonapegsomatropin.

Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.

Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.